- Home
- BETR vs NKTR Comparison
BETR vs NKTR Comparison
Compare BETR & NKTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BETR
- NKTR
- Stock Information
- Founded
- BETR 2014
- NKTR 1990
- Country
- BETR United States
- NKTR United States
- Employees
- BETR N/A
- NKTR N/A
- Industry
- BETR Finance: Consumer Services
- NKTR Biotechnology: Pharmaceutical Preparations
- Sector
- BETR Finance
- NKTR Health Care
- Exchange
- BETR Nasdaq
- NKTR Nasdaq
- Market Cap
- BETR 226.0M
- NKTR 247.9M
- IPO Year
- BETR N/A
- NKTR 1994
- Fundamental
- Price
- BETR $13.02
- NKTR $1.01
- Analyst Decision
- BETR
- NKTR Buy
- Analyst Count
- BETR 0
- NKTR 4
- Target Price
- BETR N/A
- NKTR $4.00
- AVG Volume (30 Days)
- BETR 45.1K
- NKTR 1.8M
- Earning Date
- BETR 11-13-2024
- NKTR 11-07-2024
- Dividend Yield
- BETR N/A
- NKTR N/A
- EPS Growth
- BETR N/A
- NKTR N/A
- EPS
- BETR N/A
- NKTR N/A
- Revenue
- BETR $86,179,000.00
- NKTR $93,137,000.00
- Revenue This Year
- BETR N/A
- NKTR N/A
- Revenue Next Year
- BETR N/A
- NKTR N/A
- P/E Ratio
- BETR N/A
- NKTR N/A
- Revenue Growth
- BETR N/A
- NKTR 5.53
- 52 Week Low
- BETR $11.93
- NKTR $0.42
- 52 Week High
- BETR $45.50
- NKTR $1.93
- Technical
- Relative Strength Index (RSI)
- BETR 38.17
- NKTR 30.88
- Support Level
- BETR $12.20
- NKTR $1.33
- Resistance Level
- BETR $13.75
- NKTR $1.07
- Average True Range (ATR)
- BETR 0.95
- NKTR 0.09
- MACD
- BETR -0.13
- NKTR -0.04
- Stochastic Oscillator
- BETR 30.29
- NKTR 6.26
About BETR Better Home & Finance Holding Company
Better Home & Finance Holding Co is a digital-first homeownership company whose services include mortgage, real estate, title, and homeowners insurance. The company has combined technology innovation and fresh thinking with a deep customer focus with the goal of revolutionizing the homeownership industry.
About NKTR Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, The company is focused on activating the immune system natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.